Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a risk to other vital organs.

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

Ozempic and other weight loss drugs have found their home in Kentucky, even though researchers from Washington University in ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

The weight loss drug "glucagon-like peptide-1 receptor agonists (GLP-1RA)" is showing effectiveness in various diseases and is gaining significant attention worldwide. However, not all GLP-1-based ...